Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
Joshua M. Crasner,DO,FACC,FACOI. 50 million people USA SBP>115 incr risk CAD/CVA Q 20mm incr=2X...
Transcript of Joshua M. Crasner,DO,FACC,FACOI. 50 million people USA SBP>115 incr risk CAD/CVA Q 20mm incr=2X...
Hypertension Diagnosis and
TreatmentOctober 2, 2014
Joshua M. Crasner,DO,FACC,FACOI
Incidence
50 million people USA SBP>115 incr risk CAD/CVA Q 20mm incr=2X risk JNC-8 has changed aggressive Tx Pseudo-HTN
Hypertension 2014 2
hypertension 3
ESSENTIAL HYPERTENSION
Most common HBP( > 90 %)--multifactorial increased peripheral resistance perpetuates
the process of high blood pressure and all of its secondary effects
structural hypertrophy giving rise to smooth muscle hypercontractility
pressure varies throughout the day major risk factor for coronary, renal, and
cerebrovascular disease (50% of all USA deaths)
leading cause of doctor’s visit carries prognostic value: 16X increased risk
40 y.o. smokes
hypertension 4
BP MEASUREMENT
Patient seated/back supported/feet on floor
Should rest 5 minutes prior Arm at heart level No recent caffeine, tobacco, cocaine Take medications as directed Cuff size important orthostatics
Hypertension Focus
Determine lifestyle/CV risk factors ID and Tx secondary causes ID target end organ damage
brain, heart, kidney, eyes, arteries
Hypertension 2014 5
Lifestyle/CV risk factors Cigarette smoking Obesity Inactivity Dyslipidemia Diabetes mellitus Microalbuminuria Male>55; Female>65 Fam Hx: male<55; female<65 Metabolic syndrome
Hypertension 2014 6
Secondary Causes
Endocrine Cardiac Renal
Hypertension 2014 7
Secondary CausesEndocrine
Pheochromocytoma Primary Aldosteronism Cushing’s disease
Hypertension 2014 8
Pheochromocytoma
5 P’s: pressure,pain,palps,perspiration,pallor Adrenal tumor or sympth ganglia 2-8 cases/million/year 0.5% in hypertensive patients Usually sustained HBP,sometimes paroxysmal Associated with MEN-2 a/b Plasma metanephrines most sensitive CT after plasma, then surgery
Hypertension 2014 9
Primary Aldosteronism
Adrenal oversecretion Hypertension,hypokalemia,alkalosis,hyper-
glycemia 2-15% incidence Screen w/aldo-renin ratio Unusual hypokalemia,adrenal mass, early HTN,
primary relative w/same Tx w/spironolactone,eplerenone,surgery
Hypertension 2014 10
Cushing disease
Hyperglycemia, hypokalemia,HTN 24hr cortisol Obese, moon facies, purple striae
Hypertension 2014 11
Secondary CausesCardiac
Coarctation Obstructive sleep apnea
Hypertension 2014 12
Coarctation
Constriction beyond subclavian Weak,delayed,absent FA pulse Rib notching on CXR Childhood Tx surgical
Hypertension 2014 13
Obstructive Sleep Apnea
Obese, retrognathia,large neck Loud snoring Daytime hypersomnolence, morning
headache Polysomnography test
Hypertension 2014 14
Secondary CausesRenal
Renal parenchymal disease Renovascular HTN
Renal artery stenosis Fibromuscular dysplasia
Hypertension 2014 15
Renal parenchymal disease
Common cause secondary HTN Rapid loss renal fxn if HTN-ive Creat,urine analysis,protein Decr elimination of salt and water,incr
renin, decr vasodilation all lead to incr volume/fluid retention
Dihydropyridine CCB help decr proteinuria
Hypertension 2014 16
Renovascular HTNRAS FMD
Atherosclerotic, e.g.CAD Smokers>50, new HTNSystolic/diastolic high pitched abd bruitSuspect B/L if decr renal fxn w/ use of ACEi/ARBPTA but higher restenosisRx
White female<30No family Hx HTNPTA treatment of choice
Hypertension 2014 17
hypertension 18
RED FLAGS FOR SECONDARYHYPERTENSION
Abdominal bruit: renal artery stenosis Palps,HA,pallor,perspiration:
pheochromocytoma Obesity,moon face,purple striae: Cushing’s Abd mass: polycystic kidney,hydroneph Obesity,hypersomnolence: OSAS Agitation, sweating: cocaine, ethanol,narc
w/d Hypokalemia: hyperaldosteronism Hypercalcemia: hyperparathyroidism
hypertension 19
Simple Guide to work up secondary causes of HTN
Pregnancy
Alpha methyldopa first DOC Hydralazine,some BB ok, diuretics Avoid ACEi/ARB/renin inhibitors
Hypertension 2014 20
Drugs that raise BP
BCPs EtOH Decongestants,diet pills NSAIDs MOA Cocaine Marijuana Licorice cyclosporine
Hypertension 2014 21
hypertension 22
JNC-7 Definition of HTNCATEGORY SYSTOLIC BP DIASTOLIC BP
normal < 120 and < 80
Pre-HTN 120-139 or 80-89
Hypertension
Stage 1 140-159 or 90-99
Stage 2 ≥ 160 or ≥ 100
JAMA 289; 2560-72: 2003
hypertension 23
hypertension 24
JNC-8 1. In the general population aged ≥60 years, initiate pharmacologic treatment to lower blood pressure (BP) at systolic blood pressure (SBP) ≥150 mm Hg or diastolic
blood pressure (DBP) ≥90 mm Hg and treat to a goal SBP <150 mm Hg and goal DBP <90 mm Hg. (Strong Recommendation – Grade A) In the general population aged ≥60 years, if pharmacologic treatment for high BP results in lower achieved SBP (e.g., <140 mm Hg) and treatment is well tolerated and without adverse effects on health or quality of life, treatment does not need to be adjusted. (Expert Opinion – Grade E)
2. In the general population <60 years, initiate pharmacologic treatment to lower BP at DBP ≥90 mm Hg and treat to a goal DBP <90 mm Hg. (For ages 30-59 years, Strong Recommendation – Grade A; for ages 18-29 years, Expert Opinion – Grade E)
3. In the general population <60 years, initiate pharmacologic treatment to lower BP at SBP ≥140 mm Hg and treat to a goal SBP <140 mm Hg. (Expert Opinion – Grade E)
4. In the population aged ≥18 years with chronic kidney disease (CKD), initiate pharmacologic treatment to lower BP at SBP ≥140 mm Hg or DBP ≥90 mm Hg and treat to goal SBP <140 mm Hg and goal DBP <90 mm Hg. (Expert Opinion – Grade E)
5. In the population aged ≥18 years with diabetes, initiate pharmacological treatment to lower BP at SBP ≥140 mm Hg or DBP ≥90 mm Hg and treat to a goal SBP <140 mm Hg and goal DBP <90 mm Hg. (Expert Opinion – Grade E)
6. In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), or angiotensin-receptor blocker (ARB). (Moderate Recommendation – Grade B)
7. In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB. (For general black population: Moderate Recommendation – Grade B; for black patients with diabetes: Weak Recommendation – Grade C)
8. In the population aged ≥18 years with CKD, initial (or add-on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes. This applies to all CKD patients with hypertension regardless of race or diabetes status. (Moderate Recommendation – Grade B)
9. The main objective of hypertension treatment is to attain and maintain goal BP. If goal BP is not reached within a month of treatment, increase the dose of the initial drug or add a second drug from one of the classes in recommendation 6 (thiazide-type diuretic, CCB, ACEI, or ARB). The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached. If goal BP cannot be reached with two drugs, add and titrate a third drug from the list provided. Do not use an ACEI and an ARB together in the same patient. If goal BP cannot be reached using only the drugs in recommendation 6 because of a contraindication or the need to use more than three drugs to reach goal BP, antihypertensive drugs from other classes can be used. Referral to a hypertension specialist may be indicated for patients in whom goal BP cannot be attained using the above strategy or for the management of complicated patients for whom additional clinical consultation is needed. (Expert Opinion – Grade E)
10. Although this guideline provides evidence-based recommendations for the management of high BP and should meet the clinical needs of most patients, these recommendations are not a substitute for clinical judgment, and decisions about care must carefully consider and incorporate the clinical characteristics and circumstances of each individual patient. Future guidelines should cover the full range of cardiovascular care topics, to develop an integrated approach for prevention, detection, and evaluation, along with treatment goals. Individual recommendations from discrete guidelines—such as for hypertension, cholesterol, and obesity—may not reflect the integrated care needed for many patients seen in practice. There is also a need to harmonize the hypertension guideline with other cardiovascular risk guidelines and recommendations, thereby resulting in a more coherent overall cardiovascular prevention strategy. Author(s):
Debabrata Mukherjee, M.D., F.A.C.C. (Disclosure
hypertension 25
Summary JNC 8
Patient Subgroup Target SBP Target DBP
> 60 years <150 <90
<60 years <140 <90
>18 years w CKD <140 <90
>18 years w DM <140 <90
Hypertension 2014 26James PA, et al.,JAMA,2013 Dec18
JNC 8 recommendations
General non-African population Thiazides, CCB,ACEi,or ARB initially
General African population Thiazides or CCB initially
CKD Include ACEi or ARB
Uptitrate/add RX after 1mo.if not at goal Don’t use ACEi and ARB jointly If >3 Rx needed refer to specialist
Hypertension 2014 27James PA, et al.,JAMA, 2013 Dec 18
5 of 17 JNC 8 authors disagree!!!
ANSWER??
FOLLOW THE AHA/ACC BP guidelines Start lifestyle changes and then Rx at 140/90 up to
age 80, then at 150/90 Position paper of JACC July 2014 refutes, citing
placement of mostly elderly African-American women at incr. risk for CVD mortality**
Hypertension 2014 28
**Krakoff, et al; JACC, July 29,2014;394-402
Hypertension 2014 29
hypertension 30
LAB TESTING
Urine analysis Chemistry panel Cholesterol CBC Endocrine Drug screen
hypertension 31
PHARMACOLOGIC TREATMENT
Heart failure: ACEi, ARB, diuretics, BB Diabetes: ACEi, ARB CAD/post-MI: BB, ACEi,(CCB for intol.) Systolic HTN: ACEi/ARB with diuretic, BB,
CCB Pregnancy: labetalol, methyldopa, CCB Prostate enlargement: alpha blocker Renal disease: ACEi or ARB
Summary--BP Goals
<140/90 Diabetics/CKD/High risk CAD <130/80 Reduced EF; proteinuria <120/80 Stay tuned for AHA/ACC update 2015
Hypertension 2014 32
hypertension 33
REVIEW POINTS
Familiarity with target end-organ damage
What is ideal BP? Causes of secondary hypertension Ideal agents for condition(s) Familiarity with treatment options